Edesa Biotech (EDSA) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Mereo BioPharma Group (MREO) over the past year, gaining 34.6% versus a loss of 83.3%. Over five years, MREO leads with a -83.9% price change compared with -93.3% for EDSA. Mereo BioPharma Group is the larger company by market cap ($55.9 million vs $47.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | MREO |
|---|---|---|
| Share price | $3.51 | $0.3499 |
| Market cap | $47.43M | $55.88M |
| 1-day change | -4.10% | -6.74% |
| YTD return | +157.75% | -16.09% |
| 1-year return | +34.56% | -83.34% |
| 5-year return | -93.31% | -83.95% |
| EPS (TTM) | $-1.72 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $2.37 |
| 52-week low | $0.72 | $0.20 |
| Distance from 52-week high | -82.73% | -85.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +365.24% | +460.16% |
| Average volume | 61.89K | 4.04M |
| Shares outstanding | 13.51M | 159.69M |
| Employees | 17 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed MREO by 117.9 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
EDSA vs MREO FAQ
Which is bigger, Edesa Biotech or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $55.88M compared with $47.43M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or MREO?
EDSA returned +34.56% over the past 12 months, compared with -83.34% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.